Astrazeneca

This study is testing two new vaccines, AZD4117 and AZD5315, designed to protect against dangerous bird flu strains (H5N1 and H7N9). It involves about 405 healthy adults to see if the vaccines are safe and if they trigger a strong immune response. This is an early-stage trial to …

This study aims to understand how well the drug selumetinib works and how safe it is for children in China with neurofibromatosis type 1 (NF1) who have painful, inoperable nerve tumors. It will follow about 80-100 children aged 3 to 16 who are taking the drug as part of their reg…

This study is comparing a new targeted drug called Dato-DXd against standard chemotherapy for people with advanced HR-positive, HER2-negative breast cancer that has spread and worsened after one or two prior rounds of chemotherapy. The goal is to see if the new drug helps patient…

This study is testing whether adding an experimental drug called capivasertib to standard fulvestrant hormone therapy works better than fulvestrant alone for advanced breast cancer. It's for patients whose cancer has grown or returned after previous hormone treatment. The goal is…

This large, late-stage study is testing whether adding a new drug called rilvegostomig to standard chemotherapy helps prevent bile duct or gallbladder cancer from returning after surgery. It involves over 750 patients worldwide who have had their cancer completely removed but rem…

This large, late-stage study is testing whether a new injectable medication called tozorakimab can help people with chronic obstructive pulmonary disease (COPD) who experience frequent symptom flare-ups. The trial will enroll over 1,400 adults who are already on standard inhaled …

This study tested whether a drug called durvalumab could help control Stage III non-small cell lung cancer that cannot be surgically removed. About 400 patients who had completed chemoradiation without their cancer getting worse received either durvalumab or a placebo. The main g…

This is an early-stage study to check the safety and side effects of a new injectable drug called AZD6234 in people with overweight or obesity. It will involve 104 healthy adults who will receive the drug or a placebo for 6 to 26 weeks while living at a clinic. The main goal is t…

This large, late-stage trial tested whether adding one or two immunotherapy drugs (durvalumab and tremelimumab) to standard chemotherapy could help patients with extensive-stage small cell lung cancer live longer. Nearly 1,000 adults with this advanced cancer were randomly assign…

This study is testing a new three-part treatment for people with advanced pancreatic cancer that has spread. It combines an experimental drug (AZD0171) with an existing immunotherapy (durvalumab) and standard chemotherapy. The main goals are to see if this combination is safe and…

This study is testing an experimental drug called Dato-DXd in Chinese patients with advanced non-small cell lung cancer or triple-negative breast cancer that has stopped responding to standard treatments. The drug is given as an IV infusion every three weeks to see if it can shri…

This study is testing several new drug combinations for people with advanced lung cancer that has spread. Researchers want to see if adding newer drugs to standard treatments is safe and can help control the cancer. The study involves 175 adults with stage IV non-small cell lung …

This study compared a new immunotherapy drug called durvalumab against standard chemotherapy as the first treatment for advanced non-small cell lung cancer. It involved 669 patients whose cancer had a specific biomarker (high PD-L1 expression) and had not received prior treatment…

This study is testing whether adding a second drug (oleclumab) to an existing immunotherapy (durvalumab) can better control advanced lung cancer that cannot be surgically removed. It involves 30 adults in Russia whose cancer has not worsened after completing standard chemoradiati…

This study is testing the safety of a two-part treatment for people in Spain with advanced or returning endometrial cancer. About 85 patients will first receive an immunotherapy drug with standard chemotherapy, followed by a maintenance phase with the immunotherapy plus a differe…

This global study is testing whether taking a daily pill called osimertinib for three years can prevent early-stage lung cancer from returning after surgery. It involves 390 adults whose lung cancer has been completely removed and has a specific genetic marker (EGFR mutation). Pa…

This study is testing an existing drug, trastuzumab deruxtecan, in people with advanced HER2-positive breast cancer that has progressed after prior treatments. It specifically aims to see how well the drug works in two groups: those with and without cancer that has spread to the …

This study observes how well the approved drug acalabrutinib works for chronic lymphocytic leukemia patients in real-world French hospital settings. Researchers will follow 350 patients already taking the medication to see how long they stay on it and how it affects their disease…

This large, late-stage trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation works better for people with a specific type of advanced lung cancer that cannot be surgically removed. The study involves 328 patients worldwide and co…

This large, late-stage trial is comparing a new two-drug immunotherapy combination (durvalumab + tremelimumab) against standard chemotherapy for people with advanced non-small cell lung cancer. The goal is to see if the combination helps patients live longer. The study enrolled n…

This study is for people with advanced breast cancer that is hormone-positive and has low levels of a protein called HER2. It compares a newer, targeted drug (trastuzumab deruxtecan) against standard chemotherapy chosen by the doctor. The main goal is to see if the targeted drug …

This study is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy helps people with advanced bile duct, gallbladder, or related cancers. It aims to see if this combination is safe and can help patients live longer or better control their cancer. The …

This early-stage study is testing the safety and effects of an oral medication called selumetinib in Chinese children and adults with neurofibromatosis type 1 (NF1) who have inoperable plexiform neurofibromas (tumors). Participants take the medication twice daily until their dise…

This large, late-stage study is comparing two different drug combinations for people with advanced non-small cell lung cancer that has spread. About 1200 participants will receive either a new drug called volrustomig plus standard chemotherapy, or an existing drug called pembroli…

This study is testing a drug called acalabrutinib in Chinese adults whose blood cancers have returned or not responded to previous treatments. The main goals are to check the drug's safety, how the body processes it, and whether it helps control cancers like mantle cell lymphoma …

This study is testing whether switching from a standard rescue inhaler to a combination inhaler reduces asthma flare-ups. It involves 1,500 adults with asthma who have recently had a severe flare-up. Researchers will compare how often participants need emergency care or oral ster…

This study is testing whether a weekly injection called anifrolumab can help control disease activity in adults with moderate-to-severe lupus who are already on standard treatments. About 360 participants will receive either the drug or a placebo for one year to see if it reduces…

This study is testing the safety and effects of a new weekly injection called AZD9550, both by itself and combined with another drug, AZD6234. It involves about 118 adults who are overweight or have obesity, some with and some without type 2 diabetes. The main goals are to see ho…

This study is testing an investigational drug called tozorakimab to see if it can help people with a specific type of COPD. It aims to improve lung function, reduce the frequency of symptom flare-ups (exacerbations), and ease daily symptoms like breathlessness and cough. The tria…

This study is testing whether taking a daily pill called osimertinib for five years can prevent lung cancer from returning in people who have had surgery to remove their tumor. It is for adults with a specific genetic type of non-small cell lung cancer (stages II-IIIB). The main …

This early-stage trial aimed to test a new, targeted drug called saruparib for women with advanced or recurrent ovarian cancer who have specific genetic changes (BRCA mutations). The goal was to see if the drug was safe and showed early signs of shrinking tumors before planned su…

This study is observing 155 adults with severe, uncontrolled asthma in Greece who are newly prescribed the biologic drug tezepelumab. The goal is to see how well the drug controls asthma symptoms and improves quality of life over two years in a real-world clinic setting, outside …

This study is testing a new 'sprinkle' granule form of a drug called selumetinib for very young children (ages 1 to 7) with neurofibromatosis type 1 (NF1) who have painful or problematic tumors that cannot be removed by surgery. The main goals are to find the right dose for this …

This global study is testing whether the drug selumetinib can shrink painful, inoperable tumors in adults with Neurofibromatosis Type 1 (NF1). About 145 participants will be randomly assigned to receive either selumetinib or a placebo to see which is better at reducing tumor size…

This large, late-stage trial is testing whether two immunotherapy drugs, given alone or together, can help people with advanced bladder cancer live longer than standard chemotherapy. The study enrolled over 1,100 patients who had not yet received treatment for their cancer that h…

This study is testing the safety and effectiveness of using two drugs, osimertinib and amivantamab, together as the first treatment for adults with a specific type of advanced non-small cell lung cancer (NSCLC). It will involve about 60 participants who have a cancer with a parti…

This early-stage study is testing whether combining an existing breast cancer drug (trastuzumab deruxtecan) with other cancer therapies is safe and effective for patients with advanced HER2-low breast cancer. It involves 138 adults whose cancer has spread and who have tried other…

This study is testing the safety and initial effectiveness of several new drug combinations for people with advanced bladder cancer that has continued to grow despite prior treatment. It enrolled 117 participants and assigns them to one of seven different treatment groups based o…

This study follows 152 adults with COPD in Canada for six months after their doctor prescribes a specific triple-combination inhaler (BGF/Breztri). The goal is to see how this treatment affects their breathing symptoms, quality of life, and flare-ups in a real-world setting. Rese…

This large, late-stage study is testing whether adding a new drug called baxdrostat to an existing kidney medication (dapagliflozin) works better than the existing drug alone. It involves over 2,500 adults with chronic kidney disease and high blood pressure. The goal is to see if…

This study compares two injectable medications, benralizumab and mepolizumab, for treating a rare autoimmune disease called EGPA. It involves 140 adults whose EGPA keeps coming back or hasn't responded well to standard steroid treatments. The main goal is to see which drug is bet…

This large global study is testing two new drug combinations for advanced kidney cancer that has spread. Researchers are comparing these new treatments against the current standard treatment to see which works better at controlling the cancer and helping patients live longer. The…

This study aims to understand how well the medication dapagliflozin works and how safe it is for Chinese adults with chronic kidney disease. It involves 731 participants who will take the drug to see if it can slow the worsening of their kidney function. The research focuses on m…

This study is testing whether adding a second drug, savolitinib, to a standard lung cancer drug, osimertinib, can help control cancer that has started growing again. It is for adults with a specific type of advanced non-small cell lung cancer whose disease progressed after initia…

This study allows cancer patients who were already taking osimertinib in a previous trial and are still benefiting from it to continue receiving the medication. It tracks safety and side effects while patients keep taking the drug. The goal is to provide continued access to treat…

This study is observing how well a drug called durvalumab works for people with advanced small cell lung cancer when used alongside standard chemotherapy in real-world medical settings. It follows 254 patients in France who are already receiving this approved treatment combinatio…

This study is testing if a biologic drug called tezepelumab can help people with severe, hard-to-control asthma safely reduce the amount of their daily steroid inhaler medicine. About 326 teens and adults will receive tezepelumab injections. The main goal is to see if they can lo…

This study is testing whether a medication called anifrolumab, given as a weekly injection, can safely help control the symptoms and slow the progression of systemic sclerosis (scleroderma). It will involve about 314 adults with a recent diagnosis of the disease. Participants wil…

This large, global study is testing whether adding a newer immunotherapy drug (durvalumab) to standard chemotherapy before bladder removal surgery, and then continuing the immunotherapy alone after surgery, can better control cancer and prevent it from returning. It involves over…

This study is collecting real-world information on the long-term safety and effectiveness of Saphnelo (anifrolumab) for people with systemic lupus erythematosus. It involves 1,620 patients who haven't responded well to current treatments. The goal is to monitor how the drug perfo…

This study is testing whether a medication called tezepelumab, given as an injection, can help control eosinophilic esophagitis (EoE), a chronic condition that causes painful swallowing and inflammation in the food pipe. About 368 adults and adolescents with EoE will receive eith…

This global Phase 3 trial is testing whether new drug combinations given after surgery can prevent early-stage lung cancer from returning. The study compares two experimental treatments against standard care in patients who have had their tumor completely removed but are at highe…

This study is testing whether a new drug called baxdrostat can safely lower blood pressure in adults whose high blood pressure is not controlled by their current medications. About 326 participants, who are already taking two or more blood pressure drugs, will receive either baxd…

This early-stage study is testing a new drug called AZD7789 in people with advanced lung or stomach cancers that have spread and stopped responding to standard immunotherapy. The main goals are to find a safe dose and see if the drug shows any signs of shrinking tumors. The drug …

This global study is testing whether adding new immunotherapy and targeted drugs to the treatment plan around bladder removal surgery works better than current standard care. It's for patients with muscle-invasive bladder cancer who are not eligible for or refuse the usual cispla…

This early-stage study is testing the safety and side effects of combining two cancer drugs, ceralasertib and durvalumab, in Chinese patients with advanced solid tumors. The trial involves 14 participants who have already tried standard treatments that didn't work. Researchers wi…

This study is testing whether the drug benralizumab can reduce inflammation and improve the physical structure of the lungs in people with a severe type of asthma. It involves 75 adults whose asthma is not well-controlled despite using standard high-dose inhalers. Researchers wil…

This is a first-in-human study to check if a new drug called AZD1705 is safe for people with high cholesterol. Researchers will give single and repeated doses to 96 participants and closely monitor for side effects. They will also measure how the drug moves through the body and i…

This large, late-stage study is testing if adding a drug to standard radiation treatment can better control early-stage lung cancer that cannot be surgically removed. For most participants, the drug is an immunotherapy (durvalumab) given alongside precise radiation. For a smaller…

This study is testing which of two drug combinations works better for people newly diagnosed with a type of slow-growing blood cancer (CLL/SLL). About 600 participants will receive either acalabrutinib with venetoclax or venetoclax with obinutuzumab. The goal is to see if a treat…

This study is testing whether adding the experimental drug capivasertib to standard fulvestrant treatment helps control advanced breast cancer that has worsened after hormone therapy. It involves about 258 Chinese patients with specific genetic changes in their tumors. The main g…

This study is testing whether combining two drugs, savolitinib and durvalumab, can help control advanced lung cancer in Chinese patients whose tumors have a specific genetic change called a MET alteration. The goal is to see if this combination can slow or stop the cancer's growt…

This study is monitoring the long-term safety of the asthma medication Tezspire in real-world use. It involves 416 patients with severe asthma that wasn't controlled by other treatments. The main goal is to track any side effects and understand what factors might affect the drug'…

This large global study tested whether immunotherapy drugs (given alone or in combination) work better than standard chemotherapy as a first treatment for advanced non-small cell lung cancer. It involved over 1,100 patients whose cancer had spread and who had not received prior t…

This study is testing whether adding a pill called olaparib to an existing immunotherapy drug (durvalumab) works better than the immunotherapy alone to keep advanced lung cancer from getting worse. It involves patients whose cancer has not progressed after initial chemotherapy. T…

This study tested whether a new oral medication called AZD9833 works better than the standard injected treatment (fulvestrant) for women with advanced breast cancer that has stopped responding to previous hormone therapies. It involved 240 post-menopausal women whose cancer had p…

This large, late-stage study tested whether adding a drug called olaparib to the standard treatment (abiraterone) is better at controlling advanced prostate cancer that has stopped responding to hormone therapy. It involved nearly 900 men worldwide who had not yet tried other tre…

This early-stage study is testing the safety and side effects of combining an approved lung cancer drug (osimertinib/AZD9291) with one of two other experimental drugs (AZD6094 or selumetinib). It involves about 344 adults with advanced non-small cell lung cancer that has a specif…

This study is testing whether a daily pill called AZD9291 can prevent lung cancer from returning in patients who have had their tumor completely removed by surgery. The trial involves 682 patients with early-stage lung cancer who have a specific genetic mutation. Patients are ran…

This study is testing whether a newer targeted drug, either alone or in sequence with standard chemotherapy, works better than current standard chemotherapy when given before surgery for high-risk, early-stage HER2-positive breast cancer. It aims to see if more patients can achie…

This study tested whether a higher dose (500 mg) of the hormone therapy drug fulvestrant works better than the standard dose (250 mg) for postmenopausal women with advanced breast cancer that has continued to grow after previous hormone treatment. It involved 736 women and direct…

This study is testing whether an immunotherapy drug called volrustomig can help prevent cancer from returning in women with high-risk cervical cancer. Participants are women whose cancer hasn't progressed after completing standard chemotherapy and radiation treatment. The goal is…

This study allows cancer patients who are still benefiting from durvalumab treatment in a previous trial to continue receiving it. It's designed for 214 patients who have completed their original study but need ongoing treatment. The main goal is to monitor safety while providing…

This early-stage study is testing a new oral drug called ceralasertib in combination with several other cancer treatments. The main goals are to find safe doses and see how the body processes the drug combinations in patients with advanced solid tumors that have stopped respondin…

This large Phase 3 study is testing whether adding the experimental drug capivasertib to standard paclitaxel chemotherapy works better than paclitaxel alone for advanced triple-negative breast cancer. It involves 923 patients with inoperable or spreading cancer who haven't had pr…

This early-stage study is testing two different pill versions of the same cancer drug, AZD2281, to see if the body absorbs them differently. It involves patients with advanced solid tumors that have not responded to standard treatments. The main goal is to compare the safety and …

This large Phase 3 study is comparing new drug combinations against standard treatment for people with advanced HER2-positive breast cancer that has spread. It's testing whether newer targeted drugs can help patients live longer without their cancer getting worse compared to curr…

This study is testing whether adding a new drug called savolitinib to a patient's current lung cancer medication (osimertinib) can help control the cancer after it has started growing again. It will involve about 30 adults with a specific type of advanced lung cancer. Patients wi…

This study is testing if a new oral drug called AZD0780 can safely lower 'bad' LDL cholesterol in adults with a genetic condition that causes very high cholesterol. About 455 participants will take either the new drug or a placebo pill for a year, in addition to their current cho…

This study is testing whether the drug trastuzumab deruxtecan (T-DXd) can help control advanced solid tumors that have spread and contain specific HER2 gene mutations, regardless of where the cancer started in the body. It is for adults whose cancer has worsened after prior treat…

This large, late-stage study is testing whether adding an experimental drug called capivasertib to standard hormone therapy (abiraterone) works better for men whose prostate cancer has already spread and has a specific genetic feature (PTEN deficiency). The main goal is to see if…

This study is testing whether the drug osimertinib can help prevent lung cancer from coming back after surgery. It is for patients with a specific, less common type of genetic mutation in their cancer. The goal is to see if taking this pill after surgery helps patients stay cance…

This study is testing whether two different doses of an injectable medication called tozorakimab can help people with COPD who frequently experience symptom flare-ups (exacerbations). Over 1,100 adults with moderate-to-severe COPD who are already on standard inhaler therapy will …

This study aims to see if an asthma inhaler using a new, more environmentally friendly propellant (HFO) works just as well as the same medicine using the current propellant (HFA). It involves 422 adults with asthma who will try both versions in a carefully controlled 12-week tria…

This global study is testing whether adding immunotherapy drugs (durvalumab with or without bevacizumab) to the standard liver cancer treatment called TACE helps patients live longer without their cancer getting worse. The trial involves 724 patients with liver cancer that cannot…

This study tested whether adding a drug called olaparib to standard chemotherapy (paclitaxel and carboplatin) works better than chemotherapy alone for controlling advanced ovarian cancer that had previously responded to platinum drugs. It involved 162 patients whose cancer had re…

This study is testing an investigational drug called AZD7798 to see if it can help control moderate to severe Crohn's disease. About 120 participants will be randomly assigned to receive either the drug or a placebo (inactive substance) to compare results. The main goals are to s…

This large, late-stage trial is testing whether a drug called olaparib can help keep advanced ovarian cancer from coming back after initial chemotherapy. It is for women with a specific genetic change (BRCA mutation) whose cancer responded well to first treatment. The study compa…

This study is testing a combination of two immunotherapy drugs, durvalumab and tremelimumab, as a first treatment for people with advanced liver cancer that cannot be removed by surgery. It aims to see how safe the treatment is and how well it controls the cancer. The trial is fo…

This study is testing whether adding two newer drugs, durvalumab and olaparib, to standard chemotherapy helps women with advanced or recurrent endometrial cancer live longer without their cancer getting worse. It involves about 805 women who have not yet received treatment for th…

This study is testing several new combinations of immunotherapy and chemotherapy drugs for patients with advanced triple-negative breast cancer that has spread. The goal is to find treatments that better control the cancer and help patients live longer. Researchers will enroll ab…

This study is testing whether combining an existing breast cancer drug (trastuzumab deruxtecan) with other cancer medications is safe and effective for people with advanced HER2-positive breast cancer that has spread. Researchers will enroll 245 patients to find the best doses an…

This early-stage study is testing a new drug called AZD5305 when given alongside standard hormone therapies for men with metastatic prostate cancer. The main goals are to find a safe dose and see if the combination shows early signs of helping control the cancer. The study will e…

This study is testing whether taking the approved drug selumetinib with a low-fat meal, instead of on an empty stomach, can reduce stomach-related side effects like nausea and diarrhea in teenagers with neurofibromatosis type 1 (NF1) and inoperable tumors. Researchers will measur…

This large, international study tested whether adding an immunotherapy drug (durvalumab) to standard chemotherapy helps people with advanced bile duct cancer live longer. It involved 810 patients who had not received prior treatment for their advanced disease. The main goal was t…

This study is testing whether a new injectable medication called tozorakimab can help people with COPD who keep having serious breathing flare-ups. About 1,172 adults who are former smokers and already on standard COPD inhalers will receive either the new drug or a placebo shot f…

This early-stage trial is testing whether adding an experimental oral drug called AZD6244 to standard chemotherapy is safe for people with advanced cancers like breast, lung, colon, and kidney cancer. The study will find the highest dose patients can tolerate and track how the bo…

This study is monitoring the long-term safety of selumetinib, a medication already approved for children with neurofibromatosis type 1 who have inoperable tumors. Researchers will follow 124 children aged 3-18 years across Europe and Israel for up to 6 years to track potential si…

This study is testing a treatment plan for people with a type of lung cancer that might be removable by surgery. Participants first receive a combination of immunotherapy (durvalumab) and standard chemotherapy. Doctors then decide if surgery or radiation is best, followed by more…

This large, late-stage trial is testing whether a drug called olaparib can help keep advanced ovarian cancer from coming back after successful initial chemotherapy. It involves 366 women whose cancer responded well to chemo but who do not have specific BRCA gene mutations. The st…

This large, late-stage study is testing whether adding a drug called olaparib to standard therapy (abiraterone) works better for men with advanced prostate cancer that has spread and is no longer controlled by hormone therapy alone. The goal is to see if the combination can delay…

This study is testing whether a drug called benralizumab, given as an injection every 4 weeks, can help control Hypereosinophilic Syndrome (HES). HES is a rare disorder where high levels of white blood cells cause inflammation and damage to organs. The trial will see if the drug …

This large international study is testing whether adding one of two new drugs to an existing immunotherapy helps control advanced lung cancer longer. It's for adults with Stage III non-small cell lung cancer that cannot be surgically removed and has not worsened after completing …

This study is for people with advanced non-small cell lung cancer that has continued to grow despite previous immunotherapy and chemotherapy. It compares a new two-drug combination (ceralasertib plus durvalumab) against the standard chemotherapy drug docetaxel. The main goal is t…

This study is testing if a daily pill called osimertinib can help keep stage III lung cancer from growing or spreading in people who have a specific genetic change (EGFR mutation). It is for patients whose cancer has not gotten worse after completing standard chemoradiation treat…

This large, late-stage study tested whether two immunotherapy drugs, durvalumab and tremelimumab, work better than the standard drug sorafenib for people with advanced liver cancer who haven't had other treatments. It involved over 1,300 patients worldwide. The main goal was to s…

This study is testing whether two new weekly injection drugs, AZD9550 and AZD6234, work better alone or together to help people lose weight. It involves about 360 adults with obesity or overweight who also have a weight-related health issue like high blood pressure or sleep apnea…

This early-stage study is testing a drug called acalabrutinib in Japanese adults with advanced B-cell blood cancers, such as certain types of leukemia and lymphoma. The main goal is to check the drug's safety, how the body processes it, and see if it shows any signs of fighting t…

This large, late-stage study is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation helps people with advanced esophageal cancer that cannot be surgically removed. About 640 patients worldwide will receive either the new combination or …

This study is testing a three-part treatment for liver cancer that cannot be surgically removed. First, doctors deliver tiny radioactive beads directly to the tumor. Then, patients receive two immunotherapy drugs (durvalumab and bevacizumab) to help the immune system fight the ca…

This large, late-stage trial is testing whether adding immunotherapy drugs (durvalumab alone or with tremelimumab) after standard chemoradiation can help patients with limited-stage small cell lung cancer live longer without their cancer worsening. The study involves about 730 pa…

This study is comparing a newer, targeted pill called acalabrutinib against a standard combination of chemotherapy and immunotherapy (chlorambucil plus rituximab) for adults with previously untreated chronic lymphocytic leukemia (CLL). It is for older adults or younger adults wit…

This study is for people with advanced, hormone-driven breast cancer that has developed a specific gene mutation (ESR1) while on standard treatment. It tests if switching from a common type of hormone pill (an aromatase inhibitor) to a new experimental pill (AZD9833), while keepi…

This study is collecting information on how well the medication ravulizumab works for Polish adults with paroxysmal nocturnal hemoglobinuria (PNH) in real-world clinical practice. Researchers will follow 64 patients who are already receiving this treatment through Poland's nation…

This study is testing whether adding the drug anifrolumab to standard treatment helps adults with active lupus nephritis, a serious kidney disease caused by lupus. About 360 participants will receive either anifrolumab or a placebo (dummy drug) for 76 weeks, followed by an option…

This study is testing a new oral drug called AZD5305 to see if it is safe and can help control advanced cancers. It is being tested alone and in combination with other cancer medicines in over 700 patients with various hard-to-treat solid tumors. The main goals are to find the ri…

This study is testing whether a new combination of two drugs, ceralasertib (a pill) and durvalumab (an IV infusion), can help control advanced non-small cell lung cancer. It is for adults whose cancer has continued to grow despite receiving standard immunotherapy and chemotherapy…

This study is testing an experimental drug called trastuzumab deruxtecan against standard chemotherapy for people with advanced non-small cell lung cancer that has specific HER2 gene changes. It aims to see if the new drug helps patients live longer or live longer without their c…

This study is testing whether adding one of two experimental drugs (ceralasertib or adavosertib) to an existing cancer drug (olaparib) works better than olaparib alone for people with metastatic triple-negative breast cancer. It involves about 273 patients whose cancer has worsen…

This study is testing whether adding a new drug called capivasertib to an existing hormone therapy (fulvestrant) can help control advanced breast cancer that has specific genetic changes and has started growing again after standard treatments. It will involve about 101 patients i…

This large, global study is testing whether adding one or two immunotherapy drugs (durvalumab and tremelimumab) to standard chemotherapy works better than chemotherapy alone for people with advanced bladder cancer that cannot be removed by surgery. The main goal is to see if thes…

This study is observing how well a combination of the drug Osimertinib and standard chemotherapy works for people with a specific type of advanced lung cancer (EGFR-positive NSCLC) in a real-world setting. It involves 532 adult patients who have already started this specific trea…

This early-stage study is testing the safety of a new drug called datopotamab deruxtecan when combined with immunotherapy, with or without a standard chemotherapy drug, for people with advanced non-small cell lung cancer. The main goal is to find safe dose levels and see how well…

This study is for people with advanced non-small cell lung cancer whose cancer started growing again outside the brain after initial treatment with osimertinib. It tests whether continuing osimertinib while adding standard chemotherapy works better and controls the cancer longer …

This study is testing if a drug called eplontersen can help control a serious heart disease caused by abnormal protein buildup. It involves 64 Chinese adults with this condition. For the first 24 weeks, some will receive the drug and others a placebo, followed by a longer period …

This early-stage study is testing a new drug called AZD9829 for people with certain hard-to-treat blood cancers that have a marker called CD123. The main goals are to find a safe dose and see if the drug shows early signs of fighting the cancer. It is for adults whose cancer has …

This study is for people with advanced head and neck cancer that has returned or spread and has stopped responding to standard treatments. It tests whether adding an experimental drug called monalizumab to an existing cancer drug (cetuximab) helps patients live longer and better …

This large Phase 3 trial is testing whether a new oral drug called camizestrant (AZD9833) works better than the current standard treatment when both are combined with palbociclib. The study involves 1,370 people with advanced ER-positive, HER2-negative breast cancer who haven't r…

This study is testing whether combining two existing drugs, MEDI4736 and olaparib, is safe and can help control advanced cancers that have spread or returned. It is enrolling 264 adults with specific types of ovarian, breast, lung, or stomach cancer who have not had certain prior…

This global study is testing whether two different drug combinations can prevent liver cancer from returning after patients have had successful surgery or ablation treatment. The trial involves 908 patients who are at high risk of their cancer coming back. Researchers are compari…

This study is testing several different drug combinations for people with advanced non-small cell lung cancer whose cancer has continued to grow despite receiving standard immunotherapy. The trial aims to find new treatment options for this group of patients who currently have li…

This study is testing the long-term safety and effectiveness of an investigational drug called tozorakimab for people with chronic obstructive pulmonary disease (COPD). It is for adults with COPD who have a history of symptom flare-ups and previously completed one of two related …

This study is testing a new targeted drug called savolitinib for people with an advanced form of kidney cancer called MET-driven papillary renal cell carcinoma (PRCC). It compares savolitinib directly against sunitinib, a standard treatment, to see which is better at controlling …

This study is testing if a drug called benralizumab can help people with severe eosinophilic asthma safely reduce their other daily asthma controller medications. About 504 patients in China will receive benralizumab and then try to step down their other treatments over 24 weeks.…

This large, late-stage study is testing whether adding an immunotherapy drug (durvalumab) to standard chemotherapy, given both before and after surgery, can help patients with operable stomach or gastroesophageal junction cancer live longer without their cancer returning. It comp…

This study is testing a new oral medication called AZD0780 to see if it safely lowers 'bad' LDL cholesterol in adults who already have heart disease or are at high risk for it. About 3,000 participants will take either the new drug or a placebo (inactive pill) for one year, in ad…

This large, global study is comparing a new three-drug combination to the current standard treatment for adults with advanced non-small cell lung cancer (NSCLC) that has spread and lacks certain genetic markers. The goal is to see if the new combination, which includes an experim…

This study is testing if adding standard chemotherapy to a targeted pill (osimertinib) works better than the pill alone for people with a specific type of advanced lung cancer. It enrolled about 587 adults whose cancer has a common genetic change called an EGFR mutation. The goal…

This study is testing whether a new, structured care program helps people with COPD stay healthier after they leave the hospital. The program involves training hospital staff, using a standard set of follow-up steps, and regular check-ins. Researchers are comparing this new appro…

This large, global study is testing whether adding a new immunotherapy drug called durvalumab to the standard BCG treatment works better than BCG alone for people with high-risk bladder cancer that hasn't spread into the muscle wall. The main goal is to see if the combination hel…

This study aimed to test if a detailed checklist helps doctors better manage serious bleeding in patients who take long-term blood thinners. It planned to compare hospitals using the checklist against those using their usual care methods. The trial was withdrawn before any patien…

This large, late-stage study tested whether adding one or two immunotherapy drugs (durvalumab and tremelimumab) to standard chemotherapy works better than chemotherapy alone for people newly diagnosed with advanced non-small cell lung cancer that has spread. It involved over 1,10…

This study is testing whether adding the targeted drug osimertinib before and after standard chemoradiation helps control stage III lung cancer that cannot be removed by surgery. It will involve about 76 adults whose cancer has specific EGFR gene changes. The goal is to see if th…

This study is testing whether a daily pill called olaparib can help prevent breast cancer from returning in patients who are at high risk. It is for people who have a specific inherited gene change (BRCA1/2) and have already finished their initial cancer treatments like surgery a…

This study aims to understand how well patients with chronic lymphocytic leukemia (CLL) stay on the drug acalabrutinib in everyday Italian clinics, outside of controlled trials. It will follow 151 adult patients who started the drug between May 2021 and April 2022. The main goal …

This is a first-in-human study to find a safe dose of a new drug called AZD9833 for women with advanced breast cancer that has stopped responding to standard hormone therapies. The study will test AZD9833 alone and in combination with several other cancer drugs. The main goal is …

This study is testing whether new drug combinations can help prevent triple-negative breast cancer from returning after surgery. It involves 1,174 patients who still had cancer cells present after initial chemotherapy and surgery. Participants will receive either the new drugs (d…

This study is testing whether adding a pill called olaparib to an immunotherapy drug (durvalumab) works better than the immunotherapy alone for patients with advanced bladder cancer that has spread and cannot be removed by surgery. The patients in this trial are not eligible for …

This large, late-stage study is testing whether adding a new drug called zibotentan to an existing kidney drug (dapagliflozin) can better protect kidney function in people with chronic kidney disease who have high levels of protein in their urine. The goal is to see if the combin…

This study is testing a new treatment called AZD5851, a type of CAR-T cell therapy, for adults with advanced or returning liver cancer (hepatocellular carcinoma) that has a specific marker called GPC3. The main goals are to find a safe dose and see if the treatment can shrink tum…

This study is testing a combination of three targeted drugs (acalabrutinib, venetoclax, and rituximab) for adults newly diagnosed with mantle cell lymphoma, a type of blood cancer. The main goal is to see if this chemotherapy-free approach can put the cancer into a very deep remi…

This study is testing whether a two-drug combination (AZD2811 and durvalumab) can help control extensive stage small-cell lung cancer when given as ongoing 'maintenance' therapy after initial chemotherapy. The trial involves about 31 adults whose cancer hasn't worsened after firs…

This study is testing whether a new targeted drug called datopotamab deruxtecan (Dato-DXd) works better and is safer than standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. It will involve about 644 participants who have…

This study tested whether adding a new drug called selumetinib to standard chemotherapy (docetaxel) works better than chemotherapy alone for people with advanced non-small cell lung cancer that has a specific KRAS mutation and has worsened after initial treatment. It involved 510…

This study follows 551 people with systemic lupus erythematosus (SLE) who are starting treatment with the drug anifrolumab in their regular doctor's offices. The goal is to see how well the drug controls lupus symptoms and improves quality of life over up to five years in real-wo…

This study allows ovarian and breast cancer patients who were benefiting from olaparib treatment in a previous clinical trial to continue receiving the medication. The program provides ongoing access to the drug for 185 patients who show continued clinical improvement. Participan…

This study is observing how patients with chronic lymphocytic leukemia (CLL) do on the drug acalabrutinib in real-world Spanish hospitals. It includes about 192 patients who were either starting their first treatment or switching from a similar drug due to side effects. The goal …

This large, late-stage trial is comparing a new two-drug treatment to the current standard treatment for triple-negative breast cancer. It aims to see if the new combination is better at preventing the cancer from coming back after surgery. The study involves nearly 2,000 adults …

This study is testing a combination of two treatments—the standard BCG therapy and an immunotherapy drug called durvalumab—for adults with high-risk, early-stage bladder cancer that hasn't spread into the muscle wall. The goal is to see if this combination is safe and more effect…

This study is testing if a new weekly injection called AZD6234 can help people with type 2 diabetes and obesity lose more weight. It will be given alongside their current GLP-1 medication (like Ozempic or Wegovy). The main goal is to see if adding AZD6234 leads to greater weight …

This study aims to test how well an artificial intelligence (AI) tool can predict cancer risk from lung nodules seen on chest X-rays. It will compare the AI's risk score against the assessments of expert radiologists who review CT scans. The goal is to validate the AI tool to hel…

This study aims to observe and document the real-world experience of people living with myasthenia gravis (MG) in China. It will follow about 1,200 patients of all ages to see how their symptoms, treatments, and quality of life change over time. The goal is to gather detailed inf…

This study aims to observe and describe how Chinese patients with asthma use biologic medications in real-world settings. It will follow about 200 patients for one year to see how consistently they take their prescribed biologics and what their health outcomes are. The study does…

This study is creating a large registry to track the health of over 5,000 people in China with chronic kidney disease (CKD). It aims to collect detailed information on how the disease is currently diagnosed and treated, identify where care might fall short of guidelines, and find…

This study aims to understand how doctors in Russia currently diagnose and treat adults with a rare autoimmune disorder called Neuromyelitis Optica Spectrum Disorder (NMOSD). It will observe 100 patients over three years, collecting information from their regular medical records …

This study aims to understand how well the drug acalabrutinib works for chronic lymphocytic leukemia (CLL) in everyday Romanian medical practice, outside of controlled clinical trials. It will follow 250 adult patients who started the drug in 2023 or 2024, collecting their treatm…

This early-stage study aims to understand how a new oral drug called saruparib interacts with other common medications in patients with advanced solid tumors. It will also test if different ways of making the pill affect how the body absorbs it. The main goal is to gather safety …

This early-stage study aims to check if a new experimental drug called AZD0292 is safe for people and how the body processes it. The trial involves 18 healthy Japanese volunteers who will receive either the drug or a placebo through an IV. Researchers will monitor participants cl…

This study aims to gather real-world information on how patients with severe asthma in Russia feel after starting a treatment called tezepelumab. It will follow about 110 patients aged 12 and older for one year to see if their symptoms, breathing, and need for other medications i…

This is a very early study to check if a new cancer drug called AZD6244, given as a capsule, is safe and how it moves through the body. It involved 58 adults with advanced solid tumors that had not responded to standard treatments. The main goal was to find the right dose and und…

This study is creating a detailed registry of 509 adults with systemic lupus erythematosus (SLE) in Kazakhstan. Researchers are observing how the disease progresses and what treatments patients receive in routine medical practice, without testing new therapies. The goal is to und…

This study aims to see if providing standardized training to cancer doctors in smaller city and county hospitals leads to better testing and treatment for patients with advanced non-small cell lung cancer. It will follow 1,000 patients to measure if doctors order more recommended…

This study observes how patients with chronic lymphocytic leukemia (CLL) respond to the drug acalabrutinib during routine treatment in Russian hospitals. Researchers will track 90 adult patients who recently started this medication to understand how well it works and what side ef…

This study aims to understand how long patients with chronic lymphocytic leukemia (CLL) continue taking the drug acalabrutinib in real-world German clinics. It will follow 137 patients for up to two years to see who stays on the treatment and why some might stop. The goal is to g…

This study aims to understand how Chinese patients with atypical hemolytic uremic syndrome (aHUS), a rare and serious blood disorder affecting the kidneys, are treated in real-world hospitals and what their health outcomes are. Researchers will observe 367 children and adults dia…

This study is observing how the drug durvalumab works for patients with stage III non-small cell lung cancer in real Russian clinics, after they have completed chemo-radiation therapy. It aims to collect information on the drug's safety, how long patients stay on treatment, and w…

This study aims to understand how well the targeted drug osimertinib works for patients with advanced lung cancer in real-world French hospitals, not just in controlled trials. It will follow about 274 patients who have a specific genetic mutation (EGFR) and are starting osimerti…

This early-phase study aims to understand how taking the antibiotic rifampicin affects how the body processes the experimental cancer drug cediranib. It involves 64 patients with advanced solid tumors that haven't responded to standard treatments. The main goal is to measure drug…

This study observes how 1,500 Russian patients with advanced lung cancer are treated in routine clinical practice. Researchers will collect data on what treatments doctors prescribe and how often they test for specific cancer biomarkers. The goal is to understand current treatmen…

This study aims to understand how the drug dapagliflozin is used for heart failure in real-world medical settings in Germany. It will observe 765 patients who have recently started taking the drug to see how long they stay on it, if their symptoms and quality of life improve, and…

This observational study aims to understand how doctors in Russia treat chronic lymphocytic leukemia (CLL) in real-world settings. Researchers will collect data from approximately 6,000 adult patients over two years, tracking their treatment choices and disease characteristics. T…

This is a small, early-stage study to see if a new drug called AZD7798 changes inflammation in the intestines of people with Crohn's disease. Researchers will use special PET scans to take pictures inside the gut before and after treatment. The main goal is to gather information …

This study aims to understand how advanced lung cancer is treated in real-world settings across nine countries. Researchers will analyze existing medical records from 800 patients to learn about treatment patterns and survival outcomes. The study does not involve new treatments o…

This study aims to understand how common BRCA gene mutations are in Russian patients with high-risk, early-stage breast cancer that is HER2-negative. It will observe 625 patients to see how these genetic factors relate to the treatments they receive and their long-term health out…